View in EDS HTML Full Text PDF Full Text

A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.

Saved in:
Bibliographic Details
Title: A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.
Authors: Paller AS; Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Siegfried EC; Saint Louis University and Cardinal Glennon Children's Hospital, St. Louis, MO, USA., Simpson EL; Oregon Health and Science University, Portland, OR, USA., Cork MJ; University of Sheffield, Sheffield, UK., Lockshin B; Georgetown University, Rockville, MD, USA., Kosloski MP; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Kamal MA; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Davis JD; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Sun X; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Pirozzi G; Sanofi, Bridgewater, NJ, USA., Graham NMH; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Gadkari A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Eckert L; Sanofi, Chilly-Mazarin, France., Ruddy M; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Bansal A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Source: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2021 Feb; Vol. 35 (2), pp. 464-475. Date of Electronic Publication: 2020 Nov 08.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1468-3083
DOI:10.1111/jdv.16928